/
References herein to we, us, our, the Company, and Penumbra, refer to Penumbra, Inc. and its consolidated subsidiaries unless expressly indicated or the context requires otherwise. Penumbra, the world s leading thrombectomy company, is focused on developing the most innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism such as pulmonary embol…
13.48% operating margin is respectable but not wide. ROIC at 10.71%. Suggests the business covers its cost of capital, but doesn't point to a wide moat.
Revenue up 17.5% YoY with margins expanding 12.7pp.
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Profitability & Returns
Revenue (TTM)
$1.45B
▲ +17.5% YoY
Net Income (TTM)
$171M
▲ +1168.1% YoY
Op. Margin
12.87%
▲ +12.7pp YoY
ROIC
9.66%
▲ +10.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$213M
▲ +18.8% YoY
Op. Cash Flow (TTM)
$277M
▲ +41.7% YoY
Net Debt
-$399M
Net Cash Position
Cash & Equiv.
$616M
5Y CAGR: +20.2%
Continue Research